Glucagon is a peptide hormone, exhibits therapeutic potential for metabolic disease.

HG-10-102-01 is a potent and selective inhibitor of wild-type LRRK2(IC50=23.3 nM) and the G2019S mutant(IC50=3.2 nM)

EX 527 is a potent and selective SIRT1 inhibitor with IC50 of 38 nM, exhibits >200-fold selectivity against SIRT2 and SIRT3.

Oxytocin (α-Hypophamine) acetate is a mammalian neurohypophysial hormone; its actions are mediated by specific, high-affinity oxytocin receptors; ligand of oxytocin receptor.

Diphenyleneiodonium chloride (DPI) is an inhibitor of NADPH oxidase and also a potent, irreversible, and time-, temperature-dependent iNOS/eNOS inhibitor.

XL999, a Spectrum Selective Kinase Inhibitor(TM) (SSKIs), is a potent inhibitor of key RTKs implicated in the development and maintenance of tumor vasculature and in the proliferation of some tumor cells.

3-acetyl-11-keto-β-Boswellic acid is a naturally occurring pentacyclic triterpene isolated from the gum resin exudate from the stem of the tree B. serrata (frankincense).

A non-selective group I/group II metabotropic glutamate receptor (mGluR) antagonist.

An endogenous pentapeptide with morphine-like activity that exhibits strong hepatoprotective effects..

BAY-885 is a highly potent, selective ERK5 (MAPK7) inhibitor with IC50 of 40 nM.

BI 882370 is a highly potent, selective, orally active RAF inhibitor with IC50 of 0.4, 0.8 and 0.6 nM for BRAF V600E, BRAF WT and CRAF, respectively.

Deforolimus(AP23573; MK-8669; Ridaforolimus) is a selective mTOR inhibitor with IC50 of 0.2 nM; while not classified as a prodrug, mTOR inhibition and FKBP12 binding is similar to rapamycin. IC50 value: 0.2 nM [1] Target: mTOR in vitro: Treatment of HT

Isopimpinellin has chemopreventive effects, it effectively inhibits mouse COH activity (IC50 values 19-40 microM).Isopimpinellin is a new inhibitor against the Leishmania APRT enzyme.

Corynoline is a reversible and noncompetitive inhibitor of acetylcholinesterase(AChE) with the IC50 value of 30.6 microM, which exhibits the potent anti-inflammatory and/or immunosuppressive activity, the potent inhibitory activity of corynoline for the I

COH000 is an inhibitor of Ubiquitin-like 1-activating enzyme (SUMO-activating enzyme), with an IC50 of 0.2 μM for SUMOylation in vitro.

IRE1 RNase inhibitor 8866 (MKC8866, MKC-8866) is a spectific small molecule inhibitor of mammalian IRE1 RNase activity, prevents the recombinant IRE1 protein from cleaving the synthetic XBP1 RNA probe.

JG-98 is an allosteric Hsp70 inhibitor, displays >3-fold more active, greater stability than MKT-077 against the breast cancer cell lines MDA-MB-231 and MCF-7 (EC50 of 0.4 uM and 0.7 uM, respectively).

Regadenoson is the first selective A2A receptor agonist that is approved by the FDA and is currently used clinically.

RU-301 (RU301) is a small molecule pan-TAM inhibitor that targets the TAM Ig1-Gas6 interface, blocks Gas6-dependent TAM activation.

Topiroxostat(FYX-051) is a novel and potent xanthine oxidoreductase (XOR) inhibitor with IC50 value of 5.3 nM.

A small-molecule IAP antagonist that binds to select baculovirus IAP repeat (BIR) domains resulting in dramatic induction of auto-ubiquitination activity and rapid proteasomal degradation of c-IAPs.

Ornipressin is a vasoconstrictor, haemostatic and renal agent.

Smurf1-IN-A01 is an inhibitor of negatively regulatory factor Smurf1 for promoting bone formation.

FKBP12 PROTAC dTAG-13 (dTAG-13) is an in vivo-active heterobifunctional adation tag (dTAG) small molecule that engage FKBP12F36V and CRBN, selectively degrade FKBP12F36V in a CRBN-dependent manner in cells.

FKBP12 PROTAC dTAG-7 (dTAG-7) is a cell-permeable heterobifunctional adation tag (dTAG) small molecule that engage FKBP12F36V and CRBN, selectively degrade FKBP12F36V in a CRBN-dependent manner in cells.

SRA737 is a highly potent, selective, ATP-competitive inhibitor of Chk1 with IC50 of 1.3 nM.

DJ101is a potent and metabolically stable tubulin inhibitor that can circumvent the drug efflux pumps responsible for multidrug resistance of existing tubulin inhibitors.

ACT-389949 is a novel potent and selective formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX) agonist with EC50 of 3 nM, shows potential for the treatment of inflammatory disorders..

ADH-503, reduced myeloid cell recruitment and altered the phenotypes of myeloid cells within the tumor. ADH-503 treatment increased responses to chemotherapy or radiation and also rendered normally resistant tumors sensitive to checkpoint blockade, as T c

BRITE338733 is a novel ATPase inhibitor.